vs
Side-by-side financial comparison of DOMO, INC. (DOMO) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $79.4M, roughly 1.6× DOMO, INC.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -0.5%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -0.5%).
Domo, Inc. is an American cloud software company based in American Fork, Utah, United States. It specializes in artificial intelligence, business intelligence, and data visualization and is designed to provide real-time access to business data for decision makers across the company with minimal IT involvement. It is a Software-as-a-Service (SaaS) venture.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
DOMO vs TVTX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $79.4M | $129.7M |
| Net Profit | $-10.4M | — |
| Gross Margin | 74.2% | 98.0% |
| Operating Margin | -8.7% | -25.0% |
| Net Margin | -13.1% | — |
| Revenue YoY | -0.5% | 73.4% |
| Net Profit YoY | 44.6% | — |
| EPS (diluted) | $-0.25 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $79.4M | $129.7M | ||
| Q3 25 | $79.7M | $164.9M | ||
| Q2 25 | $80.1M | $114.4M | ||
| Q1 25 | $78.8M | $81.7M | ||
| Q4 24 | $79.8M | $74.8M | ||
| Q3 24 | $78.4M | $62.9M | ||
| Q2 24 | $80.1M | $54.1M | ||
| Q1 24 | $80.2M | $41.4M |
| Q4 25 | $-10.4M | — | ||
| Q3 25 | $-22.9M | $25.7M | ||
| Q2 25 | $-18.1M | $-12.8M | ||
| Q1 25 | $-17.7M | $-41.2M | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-19.5M | $-54.8M | ||
| Q2 24 | $-26.0M | $-70.4M | ||
| Q1 24 | $-18.7M | $-136.1M |
| Q4 25 | 74.2% | 98.0% | ||
| Q3 25 | 74.8% | 99.0% | ||
| Q2 25 | 74.2% | 98.7% | ||
| Q1 25 | 74.4% | 94.3% | ||
| Q4 24 | 75.0% | 96.6% | ||
| Q3 24 | 74.3% | 97.4% | ||
| Q2 24 | 74.1% | 96.2% | ||
| Q1 24 | 76.3% | 96.4% |
| Q4 25 | -8.7% | -25.0% | ||
| Q3 25 | -9.1% | 15.1% | ||
| Q2 25 | -17.9% | -11.1% | ||
| Q1 25 | -15.6% | -52.2% | ||
| Q4 24 | -13.9% | -81.2% | ||
| Q3 24 | -18.5% | -89.3% | ||
| Q2 24 | -26.8% | -125.1% | ||
| Q1 24 | -16.6% | -336.5% |
| Q4 25 | -13.1% | — | ||
| Q3 25 | -28.8% | 15.6% | ||
| Q2 25 | -22.5% | -11.1% | ||
| Q1 25 | -22.4% | -50.4% | ||
| Q4 24 | -23.5% | — | ||
| Q3 24 | -24.9% | -87.1% | ||
| Q2 24 | -32.5% | -130.1% | ||
| Q1 24 | -23.3% | -328.9% |
| Q4 25 | $-0.25 | $0.04 | ||
| Q3 25 | $-0.56 | $0.28 | ||
| Q2 25 | $-0.45 | $-0.14 | ||
| Q1 25 | $-0.45 | $-0.47 | ||
| Q4 24 | $-0.48 | $-0.71 | ||
| Q3 24 | $-0.51 | $-0.70 | ||
| Q2 24 | $-0.69 | $-0.91 | ||
| Q1 24 | $-0.51 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $93.0M |
| Total DebtLower is stronger | $124.2M | — |
| Stockholders' EquityBook value | $-191.9M | $114.8M |
| Total Assets | $201.6M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | $47.2M | $75.2M | ||
| Q1 25 | $45.3M | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | $61.2M | $32.3M | ||
| Q1 24 | $60.9M | $43.3M |
| Q4 25 | $124.2M | — | ||
| Q3 25 | $121.9M | — | ||
| Q2 25 | $119.7M | — | ||
| Q1 25 | $117.7M | — | ||
| Q4 24 | $115.6M | — | ||
| Q3 24 | $115.2M | — | ||
| Q2 24 | $114.1M | — | ||
| Q1 24 | $113.5M | — |
| Q4 25 | $-191.9M | $114.8M | ||
| Q3 25 | $-191.5M | $73.6M | ||
| Q2 25 | $-178.7M | $32.7M | ||
| Q1 25 | $-177.2M | $32.8M | ||
| Q4 24 | $-171.2M | $59.1M | ||
| Q3 24 | $-166.4M | $-30.5M | ||
| Q2 24 | $-163.5M | $15.1M | ||
| Q1 24 | $-153.5M | $74.1M |
| Q4 25 | $201.6M | $605.2M | ||
| Q3 25 | $195.7M | $538.6M | ||
| Q2 25 | $189.7M | $555.3M | ||
| Q1 25 | $214.3M | $548.8M | ||
| Q4 24 | $190.2M | $594.1M | ||
| Q3 24 | $197.8M | $504.4M | ||
| Q2 24 | $204.4M | $551.1M | ||
| Q1 24 | $225.7M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.4M | $60.7M |
| Free Cash FlowOCF − Capex | $1.1M | — |
| FCF MarginFCF / Revenue | 1.4% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $9.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.4M | $60.7M | ||
| Q3 25 | $3.4M | $14.3M | ||
| Q2 25 | $4.0M | $5.0M | ||
| Q1 25 | $8.9M | $-42.2M | ||
| Q4 24 | $-13.7M | $-35.7M | ||
| Q3 24 | $-6.2M | $-42.5M | ||
| Q2 24 | $1.9M | $-40.2M | ||
| Q1 24 | $5.4M | $-119.0M |
| Q4 25 | $1.1M | — | ||
| Q3 25 | $1.0M | $14.2M | ||
| Q2 25 | $1.0M | — | ||
| Q1 25 | $6.7M | — | ||
| Q4 24 | $-16.2M | — | ||
| Q3 24 | $-8.4M | — | ||
| Q2 24 | $-625.0K | $-40.3M | ||
| Q1 24 | $2.9M | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | 8.6% | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 8.5% | — | ||
| Q4 24 | -20.3% | — | ||
| Q3 24 | -10.7% | — | ||
| Q2 24 | -0.8% | -74.5% | ||
| Q1 24 | 3.6% | — |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.9% | 0.1% | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 2.8% | 0.0% | ||
| Q2 24 | 3.2% | 0.2% | ||
| Q1 24 | 3.1% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
